| CAS No.: | 42461-84-7 |
|---|---|
| Formula: | C21h28f3n3o7 |
| EINECS: | 255-836-0 |
| Type: | Organic Intermediate |
| Appearance: | Powder |
| Quality: | Industrial |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Factory Supply Veterinary Drug Flunixin Meglumine Powder CAS 42461-84-7 Flunixin Meglumine |
| Appearance | White powder |
| Molecular formula | 42461-84-7 |
| Keywords | Flunixin Meglumine;Flunixin Meglumine Powder;Veterinary Drug Flunixin Meglumine |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
|
What is Flunixin meglumine? Flunisine meglumine is a strong cyclooxygenase inhibitor with analgesic, antipyretic, anti - inflammatory and anti - rheumatic effects. Analgesic effect is caused by inhibiting the synthesis of peripheral prostaglandins or their nociceptive sensitizers or their combined action, thereby blocking the conduction of nociceptive impulses. The anti-inflammatory effect of peripheral tissues may be caused by inhibiting cyclooxygenase, reducing the formation of prostaglandin precursors, and inhibiting the local inflammatory response caused by other mediators. Flunisine does not affect gastrointestinal motility in horses but may improve hemodynamics in septic shock animals. pharmacokinetics: After a single intramuscular injection of pigs (2.2mg/kg body weight), the plasma elimination half-life was 3-4 hours, and the peak concentration was 2.94 g/mL, the peak time was 0.4 hours, and the drug could still be detected in the blood after 18 hours of administration. The apparent volume of distribution was 2.0l /kg, and the bioavailability of a single neck injection was 87% |
(1) When used in conjunction with other nsaids, the adverse effects on the gastrointestinal tract can be exacerbated, such as Ulcer, bleeding
(2) Because of the high binding rate of plasma protein, when combined with other drugs, flunisine meglumine may replace other drugs combined with plasma protein or be itself replaced by other drugs, so that the effect of the drug to be replaced is enhanced, or even produce toxicity
Action and use: Antipyretic and analgesic anti-inflammatory drug, one dose, each 1kg bodyweight dog, cat 40mg., 1-2 times a day, Continuous use does not exceed 5 days
Adverse reaction : Long-term use of this product in large doses may lead to gastric ulcer and renal function injury in anima
Use with caution in patients with peptic ulcer (2)Do not use together with other nsaids
Q: What's your MOQ ?
A: For the high value product, our MOQ starts from 1g and generally starts from 10gs. For other low, price product, our MOQ starts from 100g and 1kg.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}